Lessons from the Biggest Business Tax Cut in US History
Journal of Economic Perspectives · 01.08.2024 · 38 (3) · 61-88
DOI: 10.1257/jep.38.3.61 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Economic Perspectives, erschienen am 01.08.2024. Verfasst von Gabriel Chodorow-Reich und 2 weiteren Autor:innen. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
We assess the business provisions of the 2017 Tax Cuts and Jobs Act, the biggest corporate tax cut in US history. We draw five lessons. First, corporate tax revenue fell by 40 percent due to the lower rate and more generous expensing. Second, firms with larger declines in their effective tax wedge increased investment relatively more. In aggregate, we suggest a loose consensus from the literature that total tangible corporate investment increased by 11 percent. Third, the business tax provisions increased economic growth and wages by less than advertised by the Act’s proponents, with long-run GDP higher by less than 1 percent and labor income by less than $1,000 per employee. Fourth, provisions that increase foreign investment by US-based multinationals also boost their domestic operations. Fifth, some of the expired and expiring provisions, such as accelerated depreciation, generate more investment per dollar of tax revenue than others.
Zitieren
APA
Chodorow-Reich, G., Zidar, O., & Zwick, E. (2024). Lessons from the Biggest Business Tax Cut in US History. Journal of Economic Perspectives, 38(3), 61-88. https://doi.org/10.1257/jep.38.3.61
Vancouver
Chodorow-Reich G, Zidar O, Zwick E. Lessons from the Biggest Business Tax Cut in US History. Journal of Economic Perspectives. 2024;38(3):61-88. doi:10.1257/jep.38.3.61
BibTeX
@article{ChodorowReich2024,
author = {Chodorow-Reich, Gabriel and Zidar, Owen and Zwick, Eric},
title = {Lessons from the Biggest Business Tax Cut in US History},
journal = {Journal of Economic Perspectives},
year = {2024},
volume = {38},
number = {3},
pages = {61--88},
doi = {10.1257/jep.38.3.61}
}
EUVIMED